Open AccessDifferential Gene Expression in Erlotinib-Treated Fibroblasts
Author(s) -
Karen E Wickersham,
Theresa Hodges,
Martin J. Edelman,
Yang Song,
Madaliicoleta Nan,
Susan G. Dorsey
Publication year - 2019
Publication title -
nursing research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.577
H-Index - 91
eISSN - 1538-9847
pISSN - 0029-6562
DOI - 10.1097/nnr.0000000000000330
Subject(s) - erlotinib , erlotinib hydrochloride , cancer research , biology , epidermal growth factor receptor , cancer , microbiology and biotechnology , pharmacology , genetics
Therapies targeting the epidermal growth factor receptor (EGFR) result in a painful rash, the most common and debilitating toxicity among patients with non-small cell lung cancer (NSCLC) who take EGFR tyrosine kinase inhibitor (TKI) therapy; however, predicting the development and the severity of the rash is difficult.